Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo offers hope for Tough-to-Treat blood cancers

NCT ID NCT04496349

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for adults with two types of blood cancer—T-PLL or NHL—that have not responded to or have returned after previous treatments. Researchers are testing a new drug called APG-115, either alone or combined with another drug APG-2575, to find the safest dose and see if it can shrink tumors or slow the disease. The goal is to control the cancer, not cure it, and participants will be closely monitored for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKINS LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKINS LYMPHOMA T-PROLYMPHOCYTIC LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.